文献速递心律失常

Brugada综合征恶性室性心律失常基质的评估

Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该前瞻性注册研究纳入191例Brugada综合征患者,分为有症状组(88例)和无症状组(103例),在Ajmaline试验前后进行电生理检查和基质标测或消融。结果显示,基质大小是心律失常可诱发性的唯一独立预测因子(OR 4.51,95%CI 2.51-8.09,P<0.001),基质大小4 cm²最佳识别可诱发患者(AUC 0.98,P<0.001),基质消融可预防室性快速性心律失常再诱发。

要点

  • Brugada综合征患者基质大小是恶性室性心律失常可诱发的独立预测因子。
  • Ajmaline试验后测定基质大小可识别临床标准遗漏的高危患者。
  • 基质消融与心电图正常化及无心律失常再诱发相关。

核心结论

  • Brugada综合征中动态基质变异性是致死性室性快速性心律失常的病理生理基础。
  • 基质大小与心律失常可诱发性独立相关,Ajmaline试验后测定可识别临床标准遗漏的高危患者。
  • 基质消融与心电图正常化及无心律失常再诱发相关。

研究设计与样本

  • 前瞻性注册研究,连续入选191例Brugada综合征患者,分为有症状组(n=88)和无症状组(n=103)。
  • 患者在Ajmaline试验(1 mg/kg/5 min)前后接受电生理检查和基质标测或消融。

主要发现

  • 总体而言,Ajmaline试验前53.4%的患者有室性快速性心律失常可诱发性,有症状组(65.9%)高于无症状组(42.7%;p<0.001)。
  • 无论临床表现如何,可诱发心律失常患者的基质更大、碎裂长时程心室电位更多(p<0.001)。
  • 基质更广泛时使用一个额外刺激(中位数13 cm²;p<0.001),心室颤动是更常诱发的节律(p<0.001)。
  • Ajmaline试验后,无心律失常可诱发性患者的基质特征在两组间无差异。
  • 基质大小是唯一独立预测因子(OR 4.51;95%CI 2.51-8.09;p<0.001),4 cm²最佳识别可诱发患者(AUC 0.98;p<0.001)。

关键数值与推荐

  • 基质大小是心律失常可诱发的唯一独立预测因子(OR 4.51;95%CI 2.51-8.09;p<0.001)。
  • 基质大小4 cm²最佳识别可诱发心律失常患者(AUC 0.98;p<0.001)。

临床怎么用

  • 在Brugada综合征患者中,可考虑在Ajmaline试验后评估基质大小以识别高危患者。
  • 基质消融可能有助于预防室性快速性心律失常再诱发并实现心电图正常化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend the use of implanted cardioverter-defibrillators in patients with Brugada syndrome and induced ventricular tachyarrhythmias, but there is no evidence supporting it. OBJECTIVES: This prospective registry study was designed to explore clinical and electrophysiological predictors of malignant ventricular tachyarrhythmia inducibility in Brugada syndrome. METHODS: A total of 191 consecutive selected patients with (group 1; n = 88) and without (group 2; n = 103) Brugada syndrome-related symptoms were prospectively enrolled in the registry. Patients underwent electrophysiological study and substrate mapping or ablation before and after ajmaline testing (1 mg/kg/5 min). RESULTS: Overall, before ajmaline testing, 53.4% of patients had ventricular tachyarrhythmia inducibility, which was more frequent in group 1 (65.9%) than in group 2 (42.7%; p < 0.001). Regardless of clinical presentation, larger substrates with more fragmented long-duration ventricular potentials were found in patients with inducible arrhythmias than in patients without inducible arrhythmias (p < 0.001). One extrastimulus was used in more extensive substrates (median 13 cm2; p < 0.001), and ventricular fibrillation was the more frequently induced rhythm (p < 0.001). After ajmaline, patients without arrhythmia inducibility had arrhythmia inducibility without a difference in substrate characteristics between the 2 groups. The substrate size was the only independent predictor of inducibility (odds ratio: 4.51; 95% confidence interval: 2.51 to 8.09; p < 0.001). A substrate size of 4 cm2 best identified patients with inducible arrhythmias (area under the curve: 0.98; p < 0.001). Substrate ablation prevented ventricular tachyarrhythmia reinducibility. CONCLUSIONS: In Brugada syndrome dynamic substrate variability represents the pathophysiological basis of lethal ventricular tachyarrhythmias. Substrate size is independently associated with arrhythmia inducibility, and its determination after ajmaline identifies high-risk patients missed by clinical criteria. Substrate ablation is associated with electrocardiogram normalization and not arrhythmia reinducibility. (Epicardial Ablation in Brugada Syndrome [BRUGADA_I]; NCT02641431; Epicardial Ablation in Brugada Syndrome: An Extension Study of 200 BrS Patients; NCT03106701).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pappone C, Ciconte G, Manguso F, et al. Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome. J Am Coll Cardiol. 2018. PMID: 29650119. doi:10.1016/j.jacc.2018.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。